Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2015

Published: November 2015
No. of Pages: 242
   

Global Markets Direct’s, ‘Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2015’, provides an overview of the Respiratory Syncytial Virus (RSV) Infections’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Respiratory Syncytial Virus (RSV) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Respiratory Syncytial Virus (RSV) Infections and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Respiratory Syncytial Virus (RSV) Infections
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Respiratory Syncytial Virus (RSV) Infections and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Respiratory Syncytial Virus (RSV) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Respiratory Syncytial Virus (RSV) Infections pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Respiratory Syncytial Virus (RSV) Infections
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Respiratory Syncytial Virus (RSV) Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2015

Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Respiratory Syncytial Virus (RSV) Infections Overview 11
Therapeutics Development 12
Pipeline Products for Respiratory Syncytial Virus (RSV) Infections - Overview 12
Pipeline Products for Respiratory Syncytial Virus (RSV) Infections - Comparative Analysis 13
Respiratory Syncytial Virus (RSV) Infections - Therapeutics under Development by Companies 14
Respiratory Syncytial Virus (RSV) Infections - Therapeutics under Investigation by Universities/Institutes 19
Respiratory Syncytial Virus (RSV) Infections - Pipeline Products Glance 20
Late Stage Products 20
Clinical Stage Products 21
Early Stage Products 22
Respiratory Syncytial Virus (RSV) Infections - Products under Development by Companies 23
Respiratory Syncytial Virus (RSV) Infections - Products under Investigation by Universities/Institutes 28
Respiratory Syncytial Virus (RSV) Infections - Companies Involved in Therapeutics Development 29
3-V Biosciences, Inc. 29
Ablynx NV 30
ADMA Biologics, Inc. 31
Agilvax, Inc. 32
AmVac AG 33
Aridis Pharmaceuticals LLC 34
Artificial Cell Technologies, Inc. 35
Astellas Pharma Inc. 36
AstraZeneca Plc 37
Bavarian Nordic A/S 38
Biota Pharmaceuticals, Inc. 39
Celltrion, Inc. 40
Codagenix, Inc. 41
Crucell N.V. 42
CureVac GmbH 43
DBV Technologies S.A. 44
Emergent BioSolutions Inc. 45
Evec, Inc. 46
F. Hoffmann-La Roche Ltd. 47
Folia Biotech Inc. 48
GenVec, Inc. 49
Gilead Sciences, Inc. 50
GlaxoSmithKline Plc 51
Globavir Biosciences, Inc. 52
Humabs BioMed SA 53
iBio, Inc. 54
ILiAD Biotechnologies, LLC 55
Immunovaccine, Inc. 56
Johnson & Johnson 57
Kineta, Inc. 58
mAbxience S.A. 59
MedImmune, LLC 60
Medivir AB 61
Merck & Co., Inc. 62
MSM Protein Technologies, Inc. 63
Mucosis B.V. 64
NanoBio Corporation 65
Navigen Pharmaceuticals, Inc. 66
Novavax, Inc. 67
Panacea Biotec Limited 68
Pulmocide Ltd 69
Regeneron Pharmaceuticals, Inc. 70
Romark Laboratories, L.C. 71
Sirnaomics, Inc. 72
Spider Biotech 73
Spring Bank Pharmaceuticals, Inc. 74
Takeda Pharmaceutical Company Limited 75
TechnoVax, Inc. 76
The International Biotechnology Center (IBC) Generium 77
Vaxart, Inc. 78
VBI Vaccines Inc. 79
Virometix AG 80
Respiratory Syncytial Virus (RSV) Infections - Therapeutics Assessment 81
Assessment by Monotherapy Products 81
Assessment by Combination Products 82
Assessment by Target 83
Assessment by Mechanism of Action 85
Assessment by Route of Administration 87
Assessment by Molecule Type 89
Drug Profiles 91
AK-0529 - Drug Profile 91
ALS-8112 - Drug Profile 93
ALS-8176 - Drug Profile 94
ALX-0171 - Drug Profile 95
AMV-601 - Drug Profile 96
AMV-602 - Drug Profile 97
AMV-611 - Drug Profile 98
Antisense RNAi Oligonucleotide for Respiratory Syncytial Virus Infection - Drug Profile 99
Antisense RNAi Oligonucleotides for RSV and Viral Respiratory Tract Infections - Drug Profile 100
AR-201 - Drug Profile 101
AZ-27 - Drug Profile 102
BTAC-585 - Drug Profile 103
danirixin - Drug Profile 104
DPX-RSV - Drug Profile 106
EV-046120 - Drug Profile 107
EV-046135 - Drug Profile 108
GBV-006 - Drug Profile 109
GNR-007 - Drug Profile 110
GSK-3003891A - Drug Profile 111
GSK-3389245A - Drug Profile 112
GV-2311 - Drug Profile 113
GXV - Drug Profile 115
human parainfluenza virus [type 1] + respiratory syncytial virus vaccine - Drug Profile 116
influenza + RSV vaccine - Drug Profile 117
JNJ-53718678 - Drug Profile 118
JNJ-61187165AAA - Drug Profile 119
JNJ-61187191-AAA - Drug Profile 120
MEDI-7510 - Drug Profile 121
MEDI-8897 - Drug Profile 122
Monoclonal Antibodies to Inhibit RSV-G and F Proteins for RSV Infections - Drug Profile 123
Monoclonal Antibody for Respiratory Syncytial Virus - Drug Profile 124
Monoclonal Antibody for RSV Infections - Drug Profile 125
Monoclonal Antibody to Inhibit RSV-G and RSV-F for RSV Infections - Drug Profile 126
MPE-8 - Drug Profile 127
MSM-605 - Drug Profile 128
MVA-RSV - Drug Profile 129
nitazoxanide CR - Drug Profile 130
palivizumab biosimilar - Drug Profile 132
palivizumab biosimilar - Drug Profile 133
palivizumab biosimilar - Drug Profile 134
palivizumab biosimilar - Drug Profile 135
pertussis [strain BPZE1] vaccine - Drug Profile 136
presatovir - Drug Profile 137
Recombinant Protein for RSV Infections - Drug Profile 138
REGN-2222 - Drug Profile 139
respiratory syncytial virus like particle vaccine - Drug Profile 140
respiratory syncytial virus like particle vaccines - Drug Profile 141
respiratory syncytial virus vaccine - Drug Profile 142
respiratory syncytial virus vaccine - Drug Profile 143
respiratory syncytial virus vaccine - Drug Profile 145
respiratory syncytial virus vaccine - Drug Profile 148
respiratory syncytial virus vaccine - Drug Profile 149
respiratory syncytial virus vaccine - Drug Profile 151
respiratory syncytial virus vaccine - Drug Profile 152
respiratory syncytial virus vaccine - Drug Profile 153
respiratory syncytial virus vaccine - Drug Profile 154
respiratory syncytial virus vaccine - Drug Profile 155
respiratory syncytial virus vaccine - Drug Profile 157
respiratory syncytial virus vaccine - Drug Profile 158
respiratory syncytial virus vaccine - Drug Profile 159
respiratory syncytial virus vaccine - Drug Profile 160
respiratory syncytial virus vaccine - Drug Profile 161
respiratory syncytial virus vaccine - Drug Profile 162
respiratory syncytial virus vaccine - Drug Profile 163
respiratory syncytial virus vaccine - Drug Profile 164
respiratory syncytial virus vaccine - Drug Profile 165
respiratory syncytial virus vaccine - Drug Profile 166
respiratory syncytial virus vaccine - Drug Profile 167
respiratory syncytial virus vaccine - Drug Profile 168
respiratory syncytial virus vaccine - Drug Profile 169
respiratory syncytial virus vaccine - Drug Profile 170
respiratory syncytial virus vaccine 1 - Drug Profile 171
respiratory syncytial virus vaccine 2 - Drug Profile 172
respiratory syncytial virus vaccine 2 - Drug Profile 173
respiratory syncytical virus + influenza vaccine - Drug Profile 174
RI-002 - Drug Profile 175
rOAS - Drug Profile 177
RSV [strain 98-25147-X] vaccine - Drug Profile 178
RSV vaccine - Drug Profile 179
RSV-001 - Drug Profile 180
RV-521 - Drug Profile 181
SB-105A10 - Drug Profile 182
SB-9200 - Drug Profile 184
Small Molecule for RSV - Drug Profile 186
Small Molecule to Agonize IRF-3 for Viral Infections - Drug Profile 187
Small Molecules for Respiratory Syncitial Virus and Herpes Simplex Virus Infections - Drug Profile 188
Small Molecules for Respiratory Syncytial Virus Infections - Drug Profile 189
Small Molecules for RSV and Influenza A Infections - Drug Profile 190
Small Molecules for RSV Infections - Drug Profile 191
Small Molecules to Inhibit Respiratory Syncytial Virus Fusion Protein for RSV Infections - Drug Profile 192
Small Molecules to Inhibit Viral RNA Polymerase for RSV Infections - Drug Profile 193
STP-902 - Drug Profile 194
Synthetic Peptides to Inhibit RSV-F Protein for RSV Infection - Drug Profile 195
TVB-3567 - Drug Profile 196
TVX-004IP - Drug Profile 197
VMT-3 - Drug Profile 198
Respiratory Syncytial Virus (RSV) Infections - Recent Pipeline Updates 199
Respiratory Syncytial Virus (RSV) Infections - Dormant Projects 223
Respiratory Syncytial Virus (RSV) Infections - Discontinued Products 226
Respiratory Syncytial Virus (RSV) Infections - Product Development Milestones 227
Featured News & Press Releases 227
Appendix 234
Methodology 234
Coverage 234
Secondary Research 234
Primary Research 234
Expert Panel Validation 234
Contact Us 234
Disclaimer 235

List of Tables

Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections, H2 2015 19
Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections - Comparative Analysis, H2 2015 20
Number of Products under Development by Companies, H2 2015 22
Number of Products under Development by Companies, H2 2015 (Contd..1) 23
Number of Products under Development by Companies, H2 2015 (Contd..2) 24
Number of Products under Development by Companies, H2 2015 (Contd..3) 25
Number of Products under Investigation by Universities/Institutes, H2 2015 26
Comparative Analysis by Late Stage Development, H2 2015 27
Comparative Analysis by Clinical Stage Development, H2 2015 28
Comparative Analysis by Early Stage Development, H2 2015 29
Products under Development by Companies, H2 2015 30
Products under Development by Companies, H2 2015 (Contd..1) 31
Products under Development by Companies, H2 2015 (Contd..2) 32
Products under Development by Companies, H2 2015 (Contd..3) 33
Products under Development by Companies, H2 2015 (Contd..4) 34
Products under Investigation by Universities/Institutes, H2 2015 35
Respiratory Syncytial Virus (RSV) Infections - Pipeline by 3-V Biosciences, Inc., H2 2015 36
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Ablynx NV, H2 2015 37
Respiratory Syncytial Virus (RSV) Infections - Pipeline by ADMA Biologics, Inc., H2 2015 38
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Agilvax, Inc., H2 2015 39
Respiratory Syncytial Virus (RSV) Infections - Pipeline by AmVac AG, H2 2015 40
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Aridis Pharmaceuticals LLC, H2 2015 41
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Artificial Cell Technologies, Inc., H2 2015 42
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Astellas Pharma Inc., H2 2015 43
Respiratory Syncytial Virus (RSV) Infections - Pipeline by AstraZeneca Plc, H2 2015 44
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Bavarian Nordic A/S, H2 2015 45
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Biota Pharmaceuticals, Inc., H2 2015 46
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Celltrion, Inc., H2 2015 47
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Codagenix, Inc., H2 2015 48
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Crucell N.V., H2 2015 49
Respiratory Syncytial Virus (RSV) Infections - Pipeline by CureVac GmbH, H2 2015 50
Respiratory Syncytial Virus (RSV) Infections - Pipeline by DBV Technologies S.A., H2 2015 51
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Emergent BioSolutions Inc., H2 2015 52
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Evec, Inc., H2 2015 53
Respiratory Syncytial Virus (RSV) Infections - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 54
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Folia Biotech Inc., H2 2015 55
Respiratory Syncytial Virus (RSV) Infections - Pipeline by GenVec, Inc., H2 2015 56
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Gilead Sciences, Inc., H2 2015 57
Respiratory Syncytial Virus (RSV) Infections - Pipeline by GlaxoSmithKline Plc, H2 2015 58
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Globavir Biosciences, Inc., H2 2015 59
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Humabs BioMed SA, H2 2015 60
Respiratory Syncytial Virus (RSV) Infections - Pipeline by iBio, Inc., H2 2015 61
Respiratory Syncytial Virus (RSV) Infections - Pipeline by ILiAD Biotechnologies, LLC, H2 2015 62
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Immunovaccine, Inc., H2 2015 63
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Johnson & Johnson, H2 2015 64
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Kineta, Inc., H2 2015 65
Respiratory Syncytial Virus (RSV) Infections - Pipeline by mAbxience S.A., H2 2015 66
Respiratory Syncytial Virus (RSV) Infections - Pipeline by MedImmune, LLC, H2 2015 67
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Medivir AB, H2 2015 68
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Merck & Co., Inc., H2 2015 69
Respiratory Syncytial Virus (RSV) Infections - Pipeline by MSM Protein Technologies, Inc., H2 2015 70
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Mucosis B.V., H2 2015 71
Respiratory Syncytial Virus (RSV) Infections - Pipeline by NanoBio Corporation, H2 2015 72
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Navigen Pharmaceuticals, Inc., H2 2015 73
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Novavax, Inc., H2 2015 74
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Panacea Biotec Limited, H2 2015 75
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Pulmocide Ltd, H2 2015 76
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2015 77
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Romark Laboratories, L.C., H2 2015 78
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Sirnaomics, Inc., H2 2015 79
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Spider Biotech, H2 2015 80
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Spring Bank Pharmaceuticals, Inc., H2 2015 81
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015 82
Respiratory Syncytial Virus (RSV) Infections - Pipeline by TechnoVax, Inc., H2 2015 83
Respiratory Syncytial Virus (RSV) Infections - Pipeline by The International Biotechnology Center (IBC) Generium, H2 2015 84
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Vaxart, Inc., H2 2015 85
Respiratory Syncytial Virus (RSV) Infections - Pipeline by VBI Vaccines Inc., H2 2015 86
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Virometix AG, H2 2015 87
Assessment by Monotherapy Products, H2 2015 88
Assessment by Combination Products, H2 2015 89
Number of Products by Stage and Target, H2 2015 91
Number of Products by Stage and Mechanism of Action, H2 2015 93
Number of Products by Stage and Route of Administration, H2 2015 95
Number of Products by Stage and Molecule Type, H2 2015 97
Respiratory Syncytial Virus (RSV) Infections Therapeutics - Recent Pipeline Updates, H2 2015 206
Respiratory Syncytial Virus (RSV) Infections - Dormant Projects, H2 2015 230
Respiratory Syncytial Virus (RSV) Infections - Dormant Projects (Contd..1), H2 2015 231
Respiratory Syncytial Virus (RSV) Infections - Dormant Projects (Contd..2), H2 2015 232
Respiratory Syncytial Virus (RSV) Infections - Discontinued Products, H2 2015 233

List of Figures

Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections, H2 2015 19
Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections - Comparative Analysis, H2 2015 20
Number of Products under Development by Companies, H2 2015 21
Number of Products under Investigation by Universities/Institutes, H2 2015 26
Comparative Analysis by Clinical Stage Development, H2 2015 28
Comparative Analysis by Early Stage Products, H2 2015 29
Assessment by Monotherapy Products, H2 2015 88
Number of Products by Top 10 Targets, H2 2015 90
Number of Products by Stage and Top 10 Targets, H2 2015 90
Number of Products by Top 10 Mechanism of Actions, H2 2015 92
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 92
Number of Products by Routes of Administration, H2 2015 94
Number of Products by Stage and Routes of Administration, H2 2015 94
Number of Products by Top 10 Molecule Types, H2 2015 96
Number of Products by Stage and Top 10 Molecule Types, H2 2015 96

Published By: Global Markets Direct
Product Code: Global Markets Direct13678


Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and we´┐Żll share relevant market report titles for you to explore.

Related Reports:


Why ReportsnReports.com?

  • 500,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Pharmaceuticals market as per your needs. Get the best of Pharmaceuticals research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Email Alerts

Get Email alerts about market research reports from industries and publishers of your interest: